Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ATM | Q13315 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9119354 | 0.85 | KMT2A (0.70) | MEN1KMT2AKDM4EATMALDH1A1 | |
| SCHEMBL9781400 | 0.85 | MEN1 (0.70) | MEN1KMT2AKDM4EATMALDH1A1 | |
| SCHEMBL9119369 | 0.85 | KMT2A (0.70) | MEN1KMT2AKDM4EATMALDH1A1 | |
| SCHEMBL9781310 | 0.84 | MEN1 (0.68) | MEN1KMT2AKDM4EALDH1A1CA2 | |
| SCHEMBL7893820 | 0.83 | KMT2A (0.67) | MEN1KMT2AKDM4EATMALDH1A1 | |
| SCHEMBL6095767 | 0.80 | KMT2A (0.63) | MEN1KMT2AKDM4EATMALDH1A1 | |
| SCHEMBL6095764 | 0.80 | KMT2A (0.63) | MEN1KMT2AKDM4EATMALDH1A1 | |
| SCHEMBL4883659 | 0.79 | KMT2A (0.62) | MEN1KMT2AKDM4EATMALDH1A1 | |
| SCHEMBL4846803 | 0.79 | MEN1 (0.62) | MEN1KMT2AKDM4EATMALDH1A1 | |
| SCHEMBL4883645 | 0.79 | KMT2A (0.62) | MEN1KMT2AKDM4EATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468367-B2 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-12-23 | — | — | US | disclosed |
| EP-1456203-B1 | ETHYLENE DIAMINE DERIVATIVES AND THEIR USE AS OREXIN-RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2008-08-20 | — | — | EP | disclosed |
| US-20050159421-A1 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159421-A1 | Ethylene diamine derivatives and their use as orexin-receptor antagonists | HCRTR2, HCRTR1, GRPR | MEN1 593/4885KMT2A 834/4885KDM4E 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.